Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics

SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modul...

Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546

PRINCETON, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that it will receive a milestone payment of $1 million from its partner, MedImmune, LLC for the allowance of an Investigational New Drug (IND) application for MEDI-546, a fully human antibody that tar...

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

BETHESDA and GAITHERSBURG, Md., Nov. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ) and MedImmune, Inc. today announced that new data from an ongoing Phase 1 clinical trial of MT103 in patients with late- stage non-Hodgkin's lymphoma (NHL) will be presented at the 2007 Annual Mee...

Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation

...land regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol(R). Under the settlement agreement, medimmune grants Caraco a license to certain patents, permitting Caraco to continue marketing a generic version of Ethyol(R) in the United States. The settlemen...

PDL BioPharma Announces Second Quarter 2009 Financial Results

...h in 2009 increasing from 2008 to a range of $310 to $325 million excluding medimmune royalties. Revenue growth expectations are primarily driven by increases in...nse and other professional fees. Net income after taxes for 2009 including medimmune is projected in the range of $200 to $215 million and cash generated in 200...

U.S. Expects 160 Million Doses of Swine Flu Vaccine by October

...t there was brighter news, as well. Maryland-based medimmune Inc. told U.S. officials on Thursday that it expec... "A dropper instead of a sprayer works well," medimmune vice-president Dr. Ben Machielse told the AP . medimmune said it plans to begin trials in August to make su...

FDA Approves Seasonal Flu Vaccine for 2009-2010

...line Biologicals; FluLaval, ID Biomedical Corporation; Fluvirin, Novartis Vaccines and Diagnostics Limited; Fluzone, Sanofi Pasteur Inc.; and FluMist, medimmune Vaccines Inc. More information To learn more about seasonal flu, visit the U.S. Centers for Disease Control and Prevention . ...

MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost

...am GAITHERSBURG, Md., June 29 /PRNewswire/ -- medimmune today announced the expansion of the medimmune Assistance Program for Synagis(R) (palivizumab) de...ce through no fault of their own," said Tony Zook, medimmune President. "This expansion of the...

Micromet, Inc. Reports First Quarter 2009 Financial Results

...for the further clinical development and commercialization of blinatumomab. medimmune is obligated to complete the development of the commercial scale manufactur...st. Upon the first marketing approval of blinatumomab in the United States, medimmune will have a one-time option to reacquire the commercialization rights in No...

Biotech company cofounded by BIDMC scientists targets natural killer T-cells

...D, and Mark Exley, PhD, has announced that it has closed an $8M Series A venture financing co-led by venture capital firms SV Life Sciences (SVLS) and medimmune Ventures. The company will work to develop therapies based on natural killer T-cells, with their first program focusing on treatments for asthma. ...

MedImmune in Medical Technology

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ) and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTE(R) antibody blinatumomab (MT103/MEDI-538) in pat...

Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma

- Study to Assess MEDI-528 in Stable Asthma and Exercise-Induced Bronchoconstriction - PLYMOUTH MEETING, Pa., March 18 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported that development partner, MedImmune, has initiated its fourth phase 2...

Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program

PLYMOUTH MEETING, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported that development partner MedImmune, Inc. has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persis...

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data from a preclinica...

Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. today announced data from a preclinical study in which BiTE(R) molecules targeting carcinoembryonal antigen (CEA) were shown to prevent subcutaneous tumor growth and formation of lun...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced that seven abstracts will be presented at the 2007 Pediatric Academic Societies' (PAS) Annual Meeting demonstrating the company's commitment to advancing the science of pediatric medicine. Data are fro...

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinical data on IPI-504 in a Phase I trial in patients with gastrointestinal stromal tumors (GIST) and other soft ti...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 Inhibitor Reveal Further Evidence of Safety, Tolerability, and Biological Activity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today an...

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

... GAITHERSBURG, Md., June 29 /PRNewswire/ -- medimmune continues to advance its commitment to pediatric r...an outpatient basis," said Jessie Groothuis, M.D., medimmune vice president, medical and scientific affairs, in...ys for one out of every 334 children. About medimmune MedImmune, the worldwide biologics business for...

MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants

...ic Academic Societies' Annual Meeting BALTIMORE, May 5 /PRNewswire/ -- medimmune today announced results from a recent study it sponsored, performed by the ...nd inpatient hospital stays for one out of every 334 children. About medimmune MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZ...

More>>

MedImmune in Biological News

La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery

SAN DIEGO (February 25, 2009) A major asthma discovery by a researcher at the La Jolla Institute for Allergy & Immunology has been licensed by MedImmune, a leading innovation-focused biotechnology company and wholly owned subsidiary of AstraZeneca PLC. MedImmune licensed the discovery to explore...

Yale discovery suggests protein may play a role in severe asthma

...he disease that is difficult to treat, the researchers say. The studies were done in collaboration with investigators in Wisconsin, France, and at medimmune Inc. Asthma is a chronic disease of the lung that affects more than 30 million Americans, among them nine million children. It is characterized by...

Flu shot effective against drifted influenza, nasal spray vaccine less so

...tudies had suggested that the nasal spray, sold by medimmune as FluMist, might offer better protection against ...John" Massaab, professor emeritus of epidemiology. medimmune produces it under a license with the University. ...ificantly greater protection than the flu shot. A medimmune study discussed in October at a Toronto conference...

MedImmune in Biological Technology

HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)

MedImmune Plans to Begin Shipping Seasonal Vaccine to Health Care Providers in August GAITHERSBURG, Md., June 1 /PRNewswire/ -- MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) l...

Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune

ROCKVILLE, Md., June 26 /PRNewswire/ -- Pinnacle Biologics, a private, full service pharmaceutical and biotech solutions company, today announced that it has entered into a preferred stock purchase transaction with MedImmune, LLC, pursuant to which MedImmune has acquired certain unspecified nu...

Seneca Valley High School Student Receives Science Award From MedImmune

GAITHERSBURG, Md., March 27 /PRNewswire/ -- Local biotechnology leader MedImmune announced today that Seneca Valley High School student Yiwei Li has received the distinguished "MedImmune Advancing Science for Better Health" award for her ScienceMONTGOMERY project. The company sponsored the Mon...

AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune

CAMBRIDGE, United Kingdom and GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Cambridge Antibody Technology (CAT) is changing its name to MedImmune to reflect AstraZeneca's vision for its worldwide biologics business. The new business unit will unite the resources and expertise from CAT, the pre- e...

FluMist(R) Begins Shipping for 2009-2010 Influenza Season

... GAITHERSBURG, Md., July 28 /PRNewswire/ -- medimmune announced today that it has begun shipping its sea...alth care providers throughout the United States. medimmune expects approximately 10 million doses of its triv...red every year as soon as it becomes available. A medimmune analysis suggests that starting influenza vaccinat...

Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances

...ntrol and Prevention's national immunization program and the Department of Health and Human Services. In addition, Mr. Trizzino's responsibilities at medimmune and work with the RSV (Respiratory Syncytial Virus) market should be most valuable to Novavax as we continue development of our own RSV vaccine. I am...

PDL BioPharma Announces First Quarter 2009 Financial Results

... -- In February of 2009, we received a letter from medimmune asserting that it may be entitled to pay a ...n April of 2009, we sent a letter notifying medimmune of the exercise of certain of our rights un... the exercise of which we believe precludes medimmune from being entitled to a lower royalty rate based ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

...rapy (1) demonstrating the potent anti-tumor activity of a BiTE antibody binding to carcinoembryonic antigen (CEA) and to CD3 on T cells. Micromet and medimmune are jointly developing MT111/MEDI-565, a CEA-specific BiTE, which is in pre-clinical development. CEA, also called CD66e or CEACAM5, was selecte...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

...ay announced that it is regaining from its partner medimmune the rights in North America to its most advanced B...laboration with MedImmune: In March 2009, medimmune elected to return its license rights to blinatumom...development and commercialization of blinatumomab. medimmune will complete the development of the commercial sc...

Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing

...s. This round included participation from all of Rib-X's major investors, including: Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, medimmune Ventures, Oxford Bioscience Partners, S.R. One, and Vox Equity Partners I. In the double-blind study, delafloxacin was administered intravenously...

MedImmune in Biological Definition

Biotechnology

...op 10 publicly-traded biotechnology companies, ranked by 2003 sales, are: Amgen Genentech Serono Biogen Idec Chiron Genzyme medimmune Gilead Sciences Cephalon Millennium Pharmaceuticals Biotechnology in fiction Star Trek The Breen use starships with organ...